SYSTANE® PRO vs MIEBO™ for Dry Eye Disease
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Recruiting
Phase 4
Interventional Study
Dry Eye Disease (DED)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 260 (estimated)
- Sponsor
- Indiana University · Other
Who this trial is looking for
This trial is looking for adults with evaporative dry eye disease to compare two eye treatments. Participants will receive either SYSTANE® PRO or MIEBO™ for one month and will complete surveys to check their symptoms.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old
- I can see better than 20/100 in both eyes
- My Ocular Surface Disease Index score is between 23 and 50
- My tear break up time is 5 seconds or less in both eyes
- My Schirmer I test score is 5 mm or more in both eyes
You may not be able to join if
- I have worn contact lenses in the past week
- I have used artificial tears or warm compresses in the past week
- I have a health condition that affects tear production
- I have had eye surgery in the last 12 months
- I have a history of severe eye injury or infection
- I am pregnant or breastfeeding
- I am involved in another clinical trial or study
- I am using any other eye drops or dry eye treatments
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults\>=18 years of age
* Corrected visual acuity of 20/100 or better in both eyes
* Ocular Surface Disease Index \[OSDI\] scores between 23 and 50 units \[inclusive\]
* Tear break up time score of \<=5 seconds in both eyes
* Schirmer I test (without anesthesia) \>=5 mm in bo…
Contacts